Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain
about
Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brainCrystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brainCholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brainThe Structure of Mycobacterium tuberculosis CYP125: molecular basis for cholesterol binding in a P450 needed for host infectionStructural and Biochemical Characterization of Mycobacterium tuberculosis CYP142: EVIDENCE FOR MULTIPLE CHOLESTEROL 27-HYDROXYLASE ACTIVITIES IN A HUMAN PATHOGENStructural Basis for Three-step Sequential Catalysis by the Cholesterol Side Chain Cleavage Enzyme CYP11A1In Silico and Intuitive Predictions of CYP46A1 Inhibition by Marketed Drugs with Subsequent Enzyme Crystallization in Complex with FluvoxamineBinding of a Cyano- and Fluoro-containing Drug Bicalutamide to Cytochrome P450 46A1: UNUSUAL FEATURES AND SPECTRAL RESPONSEAnalysis of oxysterols by electrospray tandem mass spectrometry.The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivoNeuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brainIdentification and developmental expression of the full complement of Cytochrome P450 genes in ZebrafishOn the mechanism of accumulation of cholestanol in the brain of mice with a disruption of sterol 27-hydroxylase.Quantification of cholesterol-metabolizing P450s CYP27A1 and CYP46A1 in neural tissues reveals a lack of enzyme-product correlations in human retina but not human brain.Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals.Sample prefractionation for mass spectrometry quantification of low-abundance membrane proteins.Oxidation of 7-dehydrocholesterol and desmosterol by human cytochrome P450 46A1.Analysis of bioactive oxysterols in newborn mouse brain by LC/MS.mRNA distribution and heterologous expression of orphan cytochrome P450 20A1Liquid chromatography-mass spectrometry utilizing multi-stage fragmentation for the identification of oxysterols.Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain.Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme ActivityCombined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPH-cytochrome P450 oxidoreductase.Steroid and protein ligand binding to cytochrome P450 46A1 as assessed by hydrogen-deuterium exchange and mass spectrometry.24-hydroxycholesterol sulfation by human cytosolic sulfotransferases: formation of monosulfates and disulfates, molecular modeling, sulfatase sensitivity, and inhibition of liver x receptor activationIntersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions.Analysis by liquid chromatography-mass spectrometry of sterols and oxysterols in brain of the newborn Dhcr7(Δ3-5/T93M) mouse: a model of Smith-Lemli-Opitz syndrome.In vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds.Drug and xenobiotic biotransformation in the blood-brain barrier: a neglected issue.Dietary intake of plant sterols stably increases plant sterol levels in the murine brain.Oxidation of endogenous N-arachidonoylserotonin by human cytochrome P450 2U1.Understanding the broad substrate repertoire of nitroreductase based on its kinetic mechanism.Targeted lipidomic analysis of oxysterols in the embryonic central nervous system.Inhibition and stimulation of activity of purified recombinant CYP11A1 by therapeutic agents.A simple and rapid method to measure cholesterol binding to P450s and other proteins.Identification of 74 cytochrome P450 genes and co-localized cytochrome P450 genes of the CYP2K, CYP5A, and CYP46A subfamilies in the mangrove killifish Kryptolebias marmoratus.Functional Magnetic Nanoparticles for Highly Efficient Cholesterol Removal.Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.Development of a novel method for quantification of sterols and oxysterols by UPLC-ESI-HRMS: application to a neuroinflammation rat model.
P2860
Q24293342-C7221DB6-3713-4884-A872-F6D730F4BB57Q24312811-B4EFB4FF-38B8-4170-A63F-47687645D2B2Q24629593-77267BCC-C168-4DC9-B613-3B8654481C10Q24644351-3591FA3B-486F-4B25-8D40-8B49E28DC9FCQ27664866-AAC802F7-AEC1-4F94-A13A-A10A3C6D4BB9Q27666316-4FC0B304-7AF4-4910-AF53-7ACE98EA9FEAQ27671113-F17E2E24-A5CC-4E87-9E1E-F94A8AE0520EQ27675738-9FF79F4B-6FAC-4EF6-943E-5AB3B47431CFQ33434723-E457A45C-4FB8-4602-8373-4AE3A5378490Q33577839-5136AA68-3174-4902-8341-6217B2D2EA26Q33586600-AE8ACE5A-BC33-495F-81AE-65B925035AB3Q33750732-B5E1C06C-0126-4B69-8ED6-7540314BC1E7Q34053150-8E1C7948-CD33-45D5-BAE0-9B73C543CD64Q34721846-35EDA32A-F704-463B-A74F-596CE05D8E41Q35001267-E58923E7-777C-42ED-AE8B-22D11B360C0EQ36141549-F379BCCB-9DD6-4C5E-9219-A9659FD61DA5Q36197660-420BA376-54B9-4094-B108-1D9A85F9B935Q36302794-5D1441F4-074B-4963-BB49-3A26427B730DQ36412665-4160E6B3-1363-4C4F-B3C1-2BEA56359B7FQ36563039-3F1FC696-DAE6-4420-857E-3379C9941088Q36658177-540A087E-8794-4F4A-9E80-FA874D00B6AFQ36941138-EF3B9D96-8B44-4A87-B899-6E462C3D5C0DQ37102311-55DD3B77-D58F-4A07-9AE8-BE001E3744BFQ37218932-92066C94-F29B-422F-B79D-298BF7D7B495Q37402754-2FF8BC7D-0061-4ACF-BC3B-FE3710BEBC72Q37627001-295FEB70-4E6A-4E5D-B998-7D293EDF05E1Q37731924-BB33B622-2BF3-4C54-87C8-09508C844DFBQ38713074-0A77EF7B-DA66-48DD-93F4-F7082C392DC5Q39103468-F401D533-550D-4F94-BA62-2C8E87578EE9Q39405942-9BCCBC9C-14D7-4251-BA5A-A34D5BB7033EQ39995855-4156CCA0-2B55-46F0-9994-0207C82ECAFFQ41942807-EFED4FAD-086B-40FB-9157-333B8EFE53FEQ43105122-37F2E7C7-8657-44E4-BE4B-9AC9451A0693Q43226857-23FA6F7C-525F-4BC6-B7B1-688ADE99AC32Q46440479-C1F3B113-CA25-4F2C-B499-252F07FDD9A2Q47130407-575F6F20-C658-44B6-9D8B-5DD2ACB72564Q47262161-478586F8-3A98-45A9-BE46-99E4508D48C1Q48221935-447A438E-439B-48FF-B06B-78484148190EQ48312809-6FC1C8A1-FB86-4CBE-94D7-A19431893110Q48363327-49E8C280-98E9-413F-BA7B-AAB4D1D9F0E0
P2860
Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Broad substrate specificity of ...... terol degradation in the brain
@ast
Broad substrate specificity of ...... terol degradation in the brain
@en
Broad substrate specificity of ...... terol degradation in the brain
@nl
type
label
Broad substrate specificity of ...... terol degradation in the brain
@ast
Broad substrate specificity of ...... terol degradation in the brain
@en
Broad substrate specificity of ...... terol degradation in the brain
@nl
prefLabel
Broad substrate specificity of ...... terol degradation in the brain
@ast
Broad substrate specificity of ...... terol degradation in the brain
@en
Broad substrate specificity of ...... terol degradation in the brain
@nl
P2093
P50
P921
P356
P1433
P1476
Broad substrate specificity of ...... terol degradation in the brain
@en
P2093
Kazuo Nakayama
Magang Shou
Natalia Mast
Ryan Norcross
Ulla Andersson
P304
14284-14292
P356
10.1021/BI035512F
P407
P577
2003-12-01T00:00:00Z